This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Hannah Billson
Hannah Billson
London +44 20 7067 2355 Download V-card

Hannah Billson is a life sciences associate advising clients on regulatory matters and English and EU litigation.

Ms. Billson has experience advising and representing clients on high profile topical issues such as the transparency of clinical trial data. She also regularly advises on marketing authorisations for medicines; CE marking of medical devices; borderline determinations; clinical trials; interactions with HCPs and advertising. On the commercial side, Ms. Billson has assisted with regulatory due diligence on a number of corporate/commercial transactions.

Contentious experience

  • Representation of a global pharmaceutical client in proceedings before the European General Court relating to the transparency of clinical trial reports.    
  • Litigation preparation and planning orphan medicines clients in relation to access to document requests and transparency.    
  • Representation of a client before the European General Court in relation to health claims on foods.
  • Representation of a client as an interested party in UK judicial review proceedings regarding borderline food supplements.
  • Representation of a global pharmaceutical client in UK judicial review proceedings relating to the use of an unlicensed medicine.

Advisory/regulatory experience

  • Regulatory advice to pharma and biotechnology companies, medical device and cosmetic manufacturers on various issues, e.g:
    • Advising a global pharmaceutical company on medicines advertising laws for using websites and social media in 32 jurisdictions across Europe, North America, Latin America, Africa and Asia;
    • Advising on the supply of in-vitro diagnostic medical devices;
    • Regulatory advice on clinical trials, including GCP breaches and the new Clinical Trial Regulation;
    • Regulatory advice to a pharmaceutical client on the pricing and reimbursement rules applicable in England;
    • Regulatory advice on pharmacovigilance obligations, including the new pharmacovigilance regime and the Penalties Regulation; and
    • Advice to food industry clients on health and nutritional claims and borderline/classification issues.

Commercial experience

  • Regulatory due diligence for and advising AstraZeneca on its agreement to transfer to the company the rights to Almirall’s respiratory franchise for an initial consideration of $875 million, and up to $1.22 billion in various milestones.
  • Regulatory due diligence for Consort Medical plc on its acquisition of Aesica Holdco Limited for approximately £230 million.
  • Drafting basic pharmacovigilance, distribution and consultancy agreements.

Pro Bono

  • Representation of a couple in UK judicial review proceedings in challenging a decision of a UK health authority to refuse medical treatment.

Previous Experience

  • Secondment to the in-house legal department of a multinational bio-technology company.